Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.00 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced, including oligodendrocytes; strongest in megakaryocyte-erythroid progenitors | 0.75 |
| chemistry Open Targets | reachable by antibody | 0.36 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 1 pathway; mostly immune signalling | 0.90 |
Knock down and overexpress RNF130 in oligodendrocytes; measure IL-1β and TNF release and surface HLA-DR and α-synuclein uptake and myelin basic protein output under oxidative stress.
- Cell type
- oligodendrocytes
- Direction
- Both arms: public data does not say which way helps.
- Molecular readout
- IL-1β and TNF release and surface HLA-DR
- Functional readout
- α-synuclein uptake and myelin basic protein output under oxidative stress
- Rule-out
- If neither arm moves IL-1β by 20% or more against non-targeting and empty-vector controls, across three independent differentiations, the hypothesis is wrong.
- Lab request
- CRISPRi knockdown and lentiviral overexpression of RNF130 in iPSC-derived oligodendrocytes; n = 3 differentiations; readouts: IL-1β and TNF release and surface HLA-DR; α-synuclein uptake and myelin basic protein output under oxidative stress. Controls: non-targeting guide, empty vector. About 8 to 10 weeks, most of it differentiation.
Sealed predictions
- RNF130 in dopamine neurons, braak-0.18 (p 0.646) → +0.12 (p 0.768)receipt 13511
- RNF130 in oligodendrocytes, braak+0.62 (p 0.073) → -0.69 (p 0.038)receipt 13510
Swarm cases
receipt 13511: RNF130 in dopamine neurons, braak
- power
- full sample -0.02 (p 0.949, n 18), 95% CI -0.48 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.02 (p 0.949, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.06 (p 0.800, n 18). could be the mix.
- skeptic
- leave-one-out range -0.14 to +0.08, sign flips 7; without severely affected donors -0.02 (p 0.949, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF130 in dopamine neurons.
case closed: nothing better to follow up.
receipt 13510: RNF130 in oligodendrocytes, braak
- power
- full sample -0.09 (p 0.715, n 18), 95% CI -0.54 to +0.39. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.13 (p 0.621, n 18). does not hold up.
- composition
- oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: +0.14 (p 0.567, n 18). could be the mix.
- skeptic
- leave-one-out range -0.23 to +0.01, sign flips 3; without severely affected donors -0.09 (p 0.715, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for RNF130 in oligodendrocytes.
case closed: nothing better to follow up.
Receipts
loading the receipts